Biology subjects

Kihara, Y.

Publications and source records attributed to Kihara, Y..

6 recordsLinked to original sources

bioRxiv2026

A phytocannabinoid-sensitive phosphorylation switch converts endocannabinoids into alternative lipid GPCR activators

Abstract: Endocannabinoids (eCBs) like anandamide and 2-arachidonoylglycerol are endogenous lipid ligands for CB1 and CB2 G protein-coupled receptors (GPCRs). Here, we show that phosphorylation of biologically important anandamide generates naturally occurring anandamide phosphate (AEAp), which switches GPCR ligand specificity to lysophosphatidic acid (LPA) receptors (LPARs) and the primate-specific bile acid sensory receptor MRGPRX4. The kinase responsible for anandamide phosphorylation was identified asdiacylglycerol kinase (DGK) theta (DGKq or DGKQ) using activity-guided brain fractionation, inhibitor profiling, recombinant reconstitution, and DGK isozyme screening. DGKQ showed noncanonical biphasic lipid kinetics and was inhibited by phytocannabinoids, most notably tetrahydrocannabinolic acid. Thus, eCBs are not only cannabinoid receptor ligands but also enzymatically adaptable lipid signals activating LPARs and MRGPRX4, thus linking metabolism of the distinct lipid LPA with Cannabis pharmacology.

biochemistry↗

bioRxiv2025

Caveolin-1 controls lineage fidelity of adult neural stem cells via lysosomal degradation of PDGFRα

Caveolae are cell-surface signaling hubs involved in stem cell proliferation and differentiation. However, the molecular details of how they influence stem cell quiescence remain poorly understood. In this study, we show that most caveolae components, particularly caveolin-1 (Cav-1), are specifically upregulated in quiescent neural stem cells (NSCs). Furthermore, we demonstrate that Cav-1 restricts platelet-derived growth factor receptor (PDGFR) signaling, a key regulator for NSC proliferation and oligodendrocyte differentiation in the adult brain, through lysosomal degradation. Genetic ablation of Cav-1 leads to aberrant NSC activation, reduced neurogenesis, and enhanced ectopic oligodendrocyte differentiation on the ventricular surface in the ventral side of the ventricular-subventricular zone (V-SVZ), a key NSC niche responsible for neuroblast differentiation. Mechanistically, we show that Cav-1 deficiency suppresses the endo-lysosomal degradation of PDGFR, leading to PDGFR accumulation and excessive signaling for oligodendrocyte differentiation. Taken together, our results uncover a crucial homeostatic mechanism wherein caveolae function as a safeguard to maintain adult NSC quiescence and lineage fidelity by controlling lysosomal turnover of PDGFR in a niche-specific manner.

neuroscience↗

bioRxiv2022

FTY720 requires vitamin B12-TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis

FTY720 (fingolimod) is a sphingosine 1-phosphate (S1P) receptor modulator and sphingosine analogue approved for multiple sclerosis (MS) therapy, which can functionally antagonize the S1P receptor, S1P1. Vitamin B12 (B12) deficiency produces neurological manifestations resembling MS. Here, we report a new mechanism where FTY720 suppresses neuroinflammation by regulating B12 metabolic pathways. Nuclear RNA-seq of c-Fos-activated astrocytes (called ieAstrocytes) from experimental autoimmune encephalomyelitis (EAE) spinal cords identified up-regulation of CD320, a transcobalamin 2 (TCN2)-B12 receptor, by S1P1 inhibition. CD320 was reduced in MS plaques. Deficiency of CD320 or dietary B12 worsened EAE and eliminated FTY720s efficacy, while concomitantly down-regulating type I interferon signaling. TCN2 functioned as a chaperone for FTY720 and sphingosine, which induced astrocytic CD320 internalization. An accompanying paper identified a requirement for astrocyte sphingosine kinases in FTY720 efficacy and its altered expression in MS brains, molecularly linking MS and B12 deficiency that can be accessed by sphingolipid/fingolimod metabolic pathways.

neuroscience↗

bioRxiv2022

Single-nucleus RNA-seq of normal-appearing brain regions in relapsing-remitting vs. secondary progressive multiple sclerosis

Multiple sclerosis (MS) is an immune-mediated demyelinating disease that alters central nervous system (CNS) functions. Relapsing-remitting MS (RRMS) is the most common form, which can transform into secondary-progressive MS (SPMS) that is associated with progressive neurodegeneration. Single-nucleus RNA sequencing (snRNA-seq) of MS lesions identified disease-related transcriptomic alterations; however, their relationship to non-lesioned MS brain regions has not been reported and which could identify prodromal or other disease susceptibility signatures. Here, snRNA-seq was used to generate high-quality RRMS vs. SPMS datasets of 33,197 nuclei from 8 normal-appearing MS brains, which revealed divergent cell type-specific changes. Notably, SPMS brains downregulated astrocytic sphingosine kinases (SPHK1/2) - the enzymes required to phosphorylate and activate the MS drug, fingolimod. This reduction was modeled with astrocyte-specific Sphk1/2 null mice in which fingolimod lost activity, supporting functionality of observed transcriptomic changes. These data provide an initial resource for studies of single cells from non-lesioned RRMS and SPMS brains.

neuroscience↗

bioRxiv2020

Lysophosphatidic acid (LPA)-antibody (504B3)validation by free-solution assay and interferometry identifies off-target binding

Antibody specificity and sensitivity is required in basic and clinical research for ensuring scientific rigor and reproducibility, while off-target cross-reactivity could generate erroneous conclusions. Lysophosphatidic acid (LPA) is a bioactive lipid being targeted clinically by antibody strategies. Here, we reexamined binding properties of a commercially available monoclonal antibody (504B3) reported as specific for LPA using a free-solution assay measured in a compensated interferometric reader. The antibody showed comparable binding affinities to LPA and non-LPA lipids including phosphatidic acid (PA) and lysophosphatidylcholine (LPC). These results may alter conclusions drawn from current and past basic and clinical studies employing anti-LPA antibodies.

molecular biology↗

bioRxiv2019

Reply: Evidence that APP gene copy number changes reflect recombinant vector contamination

In the accompanying comment1, Kim et al. concluded that somatic gene recombination (SGR) and amyloid precursor protein (APP) genomic complementary DNAs (gencDNAs) in brain are contamination artifacts and do not naturally exist. We disagree. Here we address the three types of analyses used by Kim et al. to reach their conclusions: informatic contaminant identification, plasmid PCR, and single-cell sequencing. Additionally, Kim et al. requested "reads supporting novel APP insertion breakpoints," and we now provide 10 different examples that support APP gencDNA insertion within eight chromosomes beyond wildtype APP on chromosome 21 from Alzheimers disease (AD) samples. If SGR exists as experimentally supported here and previously2,3, contamination scenarios become moot. Our informatic analyses of data generated by an independent laboratory (Park et al.)4, complement and are entirely consistent with what Lee et al.2 presented via nine distinct lines of evidence, in addition to three from a prior publication3. Plasmid contamination was identified in a single pull-down dataset after publication of Lee et al.2; however subsequent analyses did not alter any of our conclusions including those of our prior publications3,5 and plasmid contamination-free replication of this approach by ourselves and others supported the original conclusions. Novel retro-insertion sites, alterations of APP gencDNA number and form with cell type from the same brain and pathogenic SNVs occurring only in AD, all support the existence of APP gencDNAs produced by SGR.

genomics↗